Clinical Trials Logo

Thymidine Kinase 2 Deficiency clinical trials

View clinical trials related to Thymidine Kinase 2 Deficiency.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04581733 Withdrawn - Clinical trials for Thymidine Kinase 2 Deficiency

A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)

Start date: September 30, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study of the efficacy and safety of MT1621 in pediatric and adolescent patients with thymidine kinase 2 deficiency (TK2d). In order to be eligible for this study, participants must have genetic confirmation of TK2d and must not have ever received MT1621 or nucleos(t)ides before entering the study.